Search results for "LIPIDE"

Predictive factors of polycystic ovary syndrome in girls with precocious pubarche

2021

Objective: The aim of this study is to clarify, in girls with premature pubarche (PP), the influence of premature androgenization on the prevalence of polycystic ovary syndrome (PCOS). Design and patients: Ninety-nine PP girls, 63 who developed PCOS and 36 who did not develop PCOS, were retrospectively included. Clinical, anthropometric, and metabolic parameters were evaluated at the time of diagnosis of PP and after 10 years from menarche to find predictive factors of PCOS. Results: Young females with PP showed a PCOS prevalence of 64% and showed a higher prevalence of familial history of diabetes (P = 0.004) and a lower prevalence of underweight (P = 0.025) than PP-NO-PCOS. In addition, g…

Relationship between Diabetes and Ischemic Stroke: Analysis of Diabetes- Related Risk Factors for Stroke and of Specific Patterns of Stroke Associate…

2015

Diabetes and ischemic stroke are common diseases that frequently occurring together. Among patients with diabetes mellitus several factors contribute in varying degrees to the overall cerebrovascular risk including hyperglycemia, vascular risk factors such as hypertension and dyslipidemia and also genetic, demographic, and lifestyle factors and several studies have shown that people with diabetes have approximately twice the risk of ischemic stroke compared with those without diabetes. The association between ischemic stroke and diabetes is bidirectional and it is not limited to acute ischemic stroke since diabetes may contribute to a more insidious brain damage represented by lacunar infar…

Insulin resistance and familial dyslipidaemias

1999

Effects of hypolipidemic and hypoglycemic agents on atherogenic small, dense LDL in Type 2 diabetes

2011

Type 2 diabetes is associated with a cluster of inter-related plasma lipid and lipoprotein abnormalities, including reduced HDL-C, a predominance of small, dense LDL and elevated triglycerides. These abnormalities occur even in prediabetes, before blood sugars rise sufficiently in order to confirm a diagnosis of diabetes, and this transition phase incurs important cardiovascular risk. This is the rationale for paying attention to dyslipidemia through the use of the hypolipidemic, rather than hypoglycemic drugs only. A literature search (by Medline and Scopus) was performed. The authors also manually reviewed the references of selected articles for any pertinent material. Beyond the ‘quantit…

Early Markers of Cardiovascular Damage

1998

Cardiovascular (CV) disease represents at present one of the most frequent causes of morbidity and mortality in western industrialized countries. The prevalence of CV disease is increased in subjects with hypertension (HTN), diabetes mellitus (DM), dyslipidemia and central obesity. In these conditions, it is possible to detect early alterations of metabolic, hormonal, hemostatic, genetic and hemodynamic parameters, frequently associated with morphological and functional modifications of the left ventricle (LV) and the vascular system. Since these changes generally precede and are closely related to the occurrence of CV events, they may be considered early markers of CV disease. In recent ye…

Consensus document on the management of the atherogenic dyslipidaemia of the Spanish Society of Arteriosclerosis.

2017

Positioning document and summary of recommendations recently published by the Working Group on Atherogenic Dyslipemia of the Spanish Society of Arteriosclerosis and by the European Society of Arteriosclerosis.

COSMIC project : consensus on the objectives of the metabolic syndrome in clinic

2018

Juan Pedro-Botet,1 Juan F Ascaso,2,3 Vivencio Barrios,4,5 Alejandro De la Sierra,6 Javier Escalada,7,8 Jesús Millán,9 Jose M Mostaza,10 Pablo Pérez-Martínez,8,11 Xavier Pintó,8,12 Jordi Salas-Salvadó,8,13 Pedro Valdivielso14 1Lipids and Vascular Risk Unit, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, Spain; 2Endocrinology and Nutrition Service, Hospital Clínico, Universitat de Valencia, Valencia, Spain; 3INCLIVA Research Institute, Diabetes and Metabolic Diseases Ciber (Networked Biomedical Research Centres – CIBERDEM), Carlos III, Valencia, Spain; 4Cardiology Service, Hospital Universitario Ramón y Caja…

2013

A current model suggested that the somatic symptom dimension accounts for the adverse effect of depression in patients with coronary heart disease (CHD). In order to test this model we sought to determine in a large population-based sample how symptom dimensions of depression are associated with CHD, biomarkers and traditional risk factors. The associations of cognitive and somatic symptom dimensions of depression with CHD, risk factors, endothelial function, and biomarkers of inflammation and myocardial stress were analyzed cross-sectionally in a sample of n=5000 Mid-Europeans aged 35–74 years from the Gutenberg Health Study (GHS). Only the somatic symptom dimension of depression was assoc…

Dietary strategy for prevention and management of dyslipidemia: international guidelines

2012

Primary prevention of cardiovascular disease should begin with a detailed metabolic study of our patients who must follow a nutritional therapy. Recently, new guidelines ESC/EAS 2011 on the treatment of dyslipidemia have been drawn up, according to which it is possible to arrive at desirable values of cholesterol and triglycerides with a synergy between drug treatment and adequate diet therapy. At this time, Mediterranean diet has been undergoing a radical transformation: there is hyperalimentation of the Mediterranean diet in all its components. The effectiveness of the Mediterranean diet on the reduction of lipids has been demonstrated, and the problem is how to implement this diet in the…

Control de la dislipemia en grupos clínicos especiales: mujeres, ancianos, VIH, enfermedad renal crónica, pacientes con síndrome metabólico

2011

There is still some disagreement about how dyslipidemia should be treated in particular population groups. This article provides a review of indications for lipid-lowering treatment, preferably for primary prevention, in specific groups of patients: women, the elderly, and those with an HIV infection, chronic kidney disease or metabolic syndrome. Special emphasis is placed on data obtained in the JUPITER trial and in other studies of rosuvastatin.